

# Stanford

---



## Jack Silberstein

Ph.D. Student in Immunology, admitted Autumn 2017

### Bio

---

#### BIO

John "Jack" Silberstein aims to use his research and expertise to bridge the gap between basic science and drug development for autoimmunity and infectious disease. His unwavering focus is on using protein engineering, immunotherapy, and precision medicine to help solve the next wave of our global healthcare system's most burdensome diseases.

#### HONORS AND AWARDS

- Bio-X Stanford Interdisciplinary Graduate Fellowship, Stanford University (2020)
- Cancer Research Fund Award, Emerson Collective (2019)
- Best Poster Award, Stanford Bio-X Interdisciplinary Initiatives Seed Grants Program Symposium (2019)
- Featured on Cover, Targeted Therapies in Oncology (2017)

#### PROFESSIONAL AFFILIATIONS AND ACTIVITIES

- President, Stanford Biotechnology Group (2020 - present)
- Partner, Mythos Biotechnology Fund (2018 - present)
- Board Member, Stanford Medicine Alumni Association (2018 - 2020)

#### MEMBERSHIP ORGANIZATIONS

- The American Association of Immunologists, Member
- Society for Immunotherapy of Cancer, Member
- The Antibody Society, Member
- American Association for the Advancement of Science, Member

#### EDUCATION AND CERTIFICATIONS

- Bachelor of Science, Wake Forest University (2014)
- Master of Science, Johns Hopkins University (2015)

#### STANFORD ADVISORS

- Jennifer Cochran, Doctoral Dissertation Advisor (AC)

#### LINKS

- LinkedIn: <https://www.linkedin.com/in/jack-silberstein/>
- Twitter: [https://twitter.com/Jack\\_Silb](https://twitter.com/Jack_Silb)

- Google Scholar: <https://scholar.google.com/citations?hl=en&oi=ao&user=Y5i3c46h5gYC>
- PubMed Collection: <https://pubmed.ncbi.nlm.nih.gov/collections/59940261/?sort=pubdate>
- Personal Website: <https://jacksilberstein.com/>

## Publications

---

### PUBLICATIONS

- **An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA.** *Scientific reports*  
Mehta, N., Maddineni, S., Kelly, R. L., Lee, R. B., Hunter, S. A., Silberstein, J. L., Parra Sperberg, R. A., Miller, C. L., Rabe, A., Labanieh, L., Cochran, J. R.  
2020; 10 (1): 15171
- **Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*  
Armstrong, A. J., Halabi, S. n., Luo, J. n., Nanus, D. M., Giannakakou, P. n., Szmulewitz, R. Z., Danila, D. C., Healy, P. n., Anand, M. n., Rothwell, C. J., Rasmussen, J. n., Thornburg, B. n., Berry, et al  
2019; JCO1801731
- **Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.** *The Lancet. Oncology*  
Teply, B. A., Wang, H. n., Lubner, B. n., Sullivan, R. n., Rifkind, I. n., Bruns, A. n., Spitz, A. n., DeCarli, M. n., Sinibaldi, V. n., Pratz, C. F., Lu, C. n., Silberstein, J. L., Luo, et al  
2018; 19 (1): 76–86
- **Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer.** *Oncotarget*  
Boudadi, K. n., Suzman, D. L., Anagnostou, V. n., Fu, W. n., Lubner, B. n., Wang, H. n., Niknafs, N. n., White, J. R., Silberstein, J. L., Sullivan, R. n., Dowling, D. n., Harb, R. n., Nirschl, et al  
2018; 9 (47): 28561–71
- **Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer.** *The Prostate*  
Isaacsson Velho, P. n., Silberstein, J. L., Markowski, M. C., Luo, J. n., Lotan, T. L., Isaacs, W. B., Antonarakis, E. S.  
2018
- **Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.** *European urology*  
Antonarakis, E. S., Lu, C. n., Lubner, B. n., Liang, C. n., Wang, H. n., Chen, Y. n., Silberstein, J. L., Piana, D. n., Lai, Z. n., Chen, Y. n., Isaacs, W. B., Luo, J. n.  
2018
- **Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide.** *Journal of clinical oncology*  
Antonarakis, E. S., Lu, C., Lubner, B., Wang, H., Chen, Y., Zhu, Y., Silberstein, J. L., Taylor, M. N., Maughan, B. L., Denmeade, S. R., Pienta, K. J., Paller, C. J., Carducci, et al  
2017; JCO2016701961-?
- **Detection fidelity of AR mutations in plasma derived cell-free DNA ONCOTARGET**  
Goldstein, A., Toro, P. V., Lee, J., Silberstein, J. L., Nakazawa, M., Waters, I., Cravero, K., Chu, D., Cochran, R. L., Kim, M., Shinn, D., Torquato, S., Hughes, et al  
2017; 8 (9): 15651-15662
- **Clinical Utility of CLIA-Grade AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer.** *JCO precision oncology*  
Markowski, M. C., Silberstein, J. L., Eshleman, J. R., Eisenberger, M. A., Luo, J. n., Antonarakis, E. S.  
2017; 2017
- **Analytical Validation of Androgen Receptor Splice Variant 7 Detection in a Clinical Laboratory Improvement Amendments (CLIA) Laboratory Setting** *JOURNAL OF MOLECULAR DIAGNOSTICS*  
Lokhandwala, P. M., Riel, S. L., Haley, L., Lu, C., Chen, Y., Silberstein, J., Zhu, Y., Zheng, G., Lin, M., Gocke, C. D., Partin, A. W., Antonarakis, E. S., Luo, et al  
2017; 19 (1): 115-125
- **Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer.** *European urology*

Zhu, Y. n., Sharp, A. n., Anderson, C. M., Silberstein, J. L., Taylor, M. n., Lu, C. n., Zhao, P. n., De Marzo, A. M., Antonarakis, E. S., Wang, M. n., Wu, X. n., Luo, Y. n., Su, et al  
2017

- **Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate Cancer** *CURRENT UROLOGY REPORTS*

Silberstein, J. L., Taylor, M. N., Antonarakis, E. S.  
2016; 17 (4)